There was a time when CSL Ltd (ASX: CSL) could almost do no wrong in the eyes of investors. But that now feels like a very long time ago. At the time of writing, the CSL share price is down 1.77% to ...

Pressure is building on Amgen to withdraw rare disease therapy Tavneos, after the EMA's human medicine committee followed the FDA in recommending that its benefits no longer outweigh its risks. At its ...

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst ...

May 27 (Reuters) - The vaccine arm of Australian biopharmaceutical giant CSL (CSL.AX), opens new tab said on Wednesday it will discontinue ‌sales of an injectable medicine used to treat bacterial ...

For years, CSL was seen as one of Australia's safest blue-chip investments — a healthcare giant trusted by super funds, retail investors and the broader market. But in recent weeks, the biotech ...

Perplexity’s Personal Computer, its answer to OpenClaw and other local AI agents, is now available to all Mac users via its desktop app, the company announced on Thursday. As a reminder, Personal ...

CSL trades at a discount despite owning a dominant, hard-to-replicate global plasma-derived therapies infrastructure. Transformation Program targets $500–$550M in annual pre-tax cost reductions by ...

Shira is eager to hear from college students and their families about how you’re feeling about the job market. Drop her a line at shira.ovide@washpost.com. A lot of students took the advice to learn ...

The last available hemophilia gene therapy is temporarily unavailable, according to CSL Behring. Hemgenix, CSL’s one-time gene therapy for patients with hemophilia B, is experiencing a “temporary ...

At its inaugural Ask 2026 developer conference — held inside a former church in San Francisco’s North Beach — Perplexity unveiled Personal Computer, a cloud-based AI agent designed to function as a ...

C SL has broken ground for an expansion of its state-of-the-art manufacturing facility in Kankakee, Illinois. The newly expanded facility will substantially increase the global biopharma company’s ...

Eli Lilly has been scouting for drugs to follow the trail blazed by its blockbuster cardiometabolic medicines. Its latest pipeline-building deal has the pharmaceutical company paying $100 million for ...